Hoffmann-La Roche

Researchers are observing how satisfied people with relapsing-remitting multiple sclerosis are when they receive ocrelizumab as an injection under the skin instead of an intravenous infusion. The study follows about 1,800 participants across multiple countries for 12 months, incl…

Researchers are studying giredestrant, an experimental daily pill, in people with estrogen receptor-positive, HER2-negative early breast cancer. The trial enrolls about 1,500 participants, including some who switch to giredestrant after other treatments. It tracks how many people…

This trial is testing whether a combination of drugs—inavolisib plus fulvestrant, with or without palbociclib—is safe for people with a specific type of advanced breast cancer (HR+, HER2-negative) that has a PIK3CA mutation, and who also have type 2 diabetes. The main focus is on…

Researchers are testing an experimental drug called RO7830698 to see if it is safe and well tolerated. The trial includes healthy volunteers and people with chronic obstructive pulmonary disease (COPD). Participants receive either RO7830698 or a placebo, and researchers track sid…

This study tests whether combining two experimental drugs, petrelintide and enicepatide, helps adults with obesity or overweight lose more weight than taking either drug alone or a placebo. About 486 participants will receive different doses or a placebo for several months. The g…

This study tests a drug called ocrelizumab in children and teens aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see how the drug moves through the body, if it is safe, and how it affects the immune system. Participants will receive the drug as a sh…

This early-stage trial is testing an investigational drug called RO7845860, given as an injection under the skin, in people with relapsing multiple sclerosis (MS). The main goals are to check the drug's safety, how the body handles it, and its effects on immune cells. The study w…

This phase 2 trial is testing whether an experimental drug called RO7568282 can slow the worsening of motor symptoms in people with early-stage Parkinson's disease. Participants, aged 40 to 85, must be on stable levodopa monotherapy. The study compares the drug against a placebo …

This trial tests whether an experimental drug called RO7568282 can slow the progression of early Alzheimer's disease. About 450 people with mild cognitive impairment or mild dementia due to Alzheimer's will receive either the drug or a placebo for 72 weeks. Researchers will measu…

Researchers are testing whether a single dose of the antiviral drug baloxavir marboxil can stop influenza from spreading among people who live with someone who has the flu. The trial enrolls households in China where one person has confirmed influenza and up to five other members…